Larvol Delta - Advances-in-AAV9-Gene-Therapy-for-CLN3--Update-on-the-Phase-III-Clinical-Trial-Indicating-Lasting-Efficacy-at-5-Years-Post-Dosing-and-Next-Steps-in-Program-Development

AT-GTX-502 - Amicus

https://www.sciencedirect.com/science/article/pii/S1525001625003028

Emily De Los Reyes 1; Shawn Aylward 1; Jessica Scherr 1; Charles Albright 1; Cassandra Dennys 2; Shibi Likhite 1; Deep Singh 3; Jill Weimer 4; PJ Anand 5; Kathrin Meyer 6

Apr 10, 2025